Association of anti-programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma
Source: MDLinx, September 2020
In this cohort study involving 56 patients with metastatic melanoma, researchers sought to assess the risk of a recurrence of immune toxic effects correlated with anti-programmed cell death 1 antibody (anti–PD-1) therapy after discontinuation of ipilimumab monotherapy due to severe adverse events (AEs).
This investigation was carried out at 19 French melanoma referral centers involved patients with metastatic melanoma who experienced severe immune-related AEs following ipilimumab therapy and then were treated with anti–PD-1 therapy between February 1, 2013, and December 31, 2016.
In total, 12 patients (21%) felt grade 3 or 4 immune-related AEs, and among these patients, 4 (33%) presented with the same immune-related AE as with ipilimumab therapy.
